PBAC's latest decision on Topotecan: Recommended (2020). Considered for Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy; small cell lung carcinoma after failure of first-line chemotherapy; and in combination with cisplatin for treatment of patients with histologically confirmed Stage IC-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2010
Submissions
2
2010 → 2020
Eligible population
Patients with advanced metastatic ovarian cancer who have failed prior therapy including a platinum compound; also indicated for small cell lung cancer and cervical cancer as per TGA registration.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Key trials
O'Brien et al
Comparator
Hycamtin (topotecan)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as Topotecan Accord is bioequivalent to Hycamtin with no expected improvement in efficacy or reduction in toxicity.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2010) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2010: Not recommended · Authority Required — ICER $45k/QALY